Marathon Partners Pushes Dr. Martens for Strategic Review, Possible Sale
Published
1 month ago
on
By
The New York-based firm argues Dr. Martens’ stalled earnings growth and sharp share price drop of 83 percent since its public listing in 2021 have decoupled its valuation from its intrinsic value.
